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Dear Sir,
Of all solid tumors in humans the molecu-
lar carcinogenesis of colorectal cancer (CRC)
is one of the best understood. However, the
role of alterations of the retinoblastoma sus-
ceptibility tumor suppressor gene RB-1 with
regard to malignant transformation and met-
astatic progression of these neoplasms is still
poorly comprehended. RB-1 was the first tu-
mor suppressor gene to be discovered and is
located on chromosome 13q14. Its overall
size amounts to 200 kB of genomic DNA,
including 27 exons (4,750 bp), encoding a
nuclear phosphoprotein consisting of 928
amino acids (pRB110) that can be detected in
all human tissues and is phosphorylated by
activated cyclin-dependent kinases during the
G1-phase. Recent data suggest that pRB110
may play an important role in switching the
cell cycle towards the S-phase by releasing its
covalent binding partner, transcription factor
E2-F, at the restriction point [1, 2].
Inherited RB inactivation is associated
with the development of retinoblastomas in
children. Survivors of inherited retinoblasto-
ma have an increased risk of developing sec-
ondary tumors, mainly osteogenic and soft
tissue sarcomas. In other tumors, RB-1 inacti-
vation is found with varying frequency. How-
ever, there is no doubt that alterations of one
or more contributors to the RB-1/E2F path-
way (p16, cdk4, RB-1 and E2F) play a crucial
role in the majority of human malignancies.
This may also apply to CRC: although so far
no mutations of RB-1 in colorectal cancer
have been reported, various researchers have
discussed a putative role of RB alterations in
these tumors in the past [3, 4].
Evidence of the importance of RB-1 al-
terations in colorectal carcinogenesis was
mainly provided by the finding that altera-
tions of allelic copy numbers affecting the
RB locus have been found in 30–50% of
colorectal cancers. Among those, allelic am-
plifications that are specific for the genetic
location of RB-1 occurred in 10%, whereas
the frequency of allelic losses was not in-
creased in most studies [5, 6]. In all CRCs
which were analyzed with regard to the num-
ber of RB allelic copies, an intact RB trans-
cript could be detected as well as an intact
protein, and protein synthesis was increased
in some cases. In a certain percentage of
colorectal cancers one can also find an al-
tered state of phosphorylation or increased
DNA-binding capacity of pRB110, thus
leading to the hypothesis of a causal connec-
tion between RB allelic multiplications and
elevated pRB110 synthesis in colorectal can-
cer [3, 5, 7, 8]. However, this would be con-
tradictory to previous findings describing
RB-1 as a tumor suppressor gene, whose
overexpression is not thought to promote
malignant transformation, but should in-
stead hamper the growth of cells.
Taken together, available data on RB
alterations in colorectal cancer are somewhat
confusing, and, in particular, it is still unre-
solved whether RB-1 exon mutations con-
tribute to colorectal carcinogenesis at all. Re-
markably, the authors of one previous study
failed to demonstrate mutations of the RB
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Fig. 1. a–c Autoradiographies of SSCP-PCR electrophoresis products of Rb exons 11–17 at 1% (a), 16–20 at 0.5% (b)
and 19–23 at 1% (c) acrylamide concentrations.
Table 1. Patients characteristics
Total number of patients 29
Male/female 20/9
Age, years
Mean/median 61.3/65
Range 15–82
Primary tumor site
Colon cancer 22
Rectal cancer/cancer of the
rectosigmoid transition 3/1
Colorectal cancer,
undetermined site 3
exon 21 (which is coding a part of the RB
oncogene binding region) in 6 CRC cell lines
by denaturating gel electrophoresis, although
alterations in RB allelic copy number had
been proven in most of those samples before.
On this background, analyzing a larger num-
ber of specimens of patients with colorectal
cancer may be helpful to answer the question
of whether RB-1 mutations actually play a
role in colorectal carcinogenesis before fur-
ther investigations may be proceeded.
We therefore performed mutational
analysis of RB exons 11–23 by using a
‘single-strand conformation polymorphism
(SSCP)’-analysis of PCR products (SSCP-
PCR) in surgical specimens obtained from
29 patients with colorectal liver metastases,
who had undergone hepatic resection be-
tween 1989 and 1993. RB exons 11–23 con-
tain the most important protein domains
(oncogene binding pockets). We chose liver
metastases as an accumulation of genetic ab-
normalities is generally observed in ad-
vanced and metastatic tumors. Four samples
of primary colorectal cancer and 2 samples
of healthy colon epithelium for reference
purposes were also investigated. The pa-
tients’ characteristics are summarized in ta-
ble 1.
Tumor preparation, RNA isolation, and
first-strand synthesis were performed as de-
scribed before, as well as a standard PCR-
approach of the RB-1 gene [10, 11].
Primer sequences were:
Rb1a (5)) ATT CCT CCA CAC ACT
CCA GT
Rb 1b (5)) GAA TCA AGA TTC TGA
GAT GT (exons 11–17)
Rb 2a (5)) GGT TGT AAT GGC CAC
ATA TA
Rb 2b (5)) GAT AGG CTA GCC GAT
ACA CT (exons 16–20)
Rb 3 (5)) CCA GAC CCA GAA GCC
ATT GA
Rb 4 (5)) CCA GGA ATC CGT AAG
GGT GA (exons 19–23)
SSCP-PCR consisted of a PCR with ra-
diolabelled [32P]dCTP, endonuclease restric-
tion of PCR products, high-resolution gel
electrophoresis of the restriction products,
and autoradiography of the electrophoresis
gel. PCR was performed with cDNA of 50 ng
RNA in a total volume of 10 Ìl, containing
200 ÌM dATP, dTTP, dGTP, 4 ÌM dCTP,
0,1 Ìl radiolabelled dCTP (1 ÌCi/Ìl, Du-
Pont, Homburg, Germany), 1 ! PCR buff-
er, 0.5 ÌM primer each, and 1 U Taq – poly-
merase (Perkin Elmer) for 30 cycles (cp. cita-
tions above) before PCR products were
cleaved using appropriate restriction endo-
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Fig. 2. Autoradiography of the electrophore-
sis gel of SSCP-PCR restriction product of
exons 19–23 in samples 27 and 32. Missing
bands of the large (265-bp) fragment.
nucleases (Boehringer Mannheim, Germa-
ny). In detail, we used Acc1 to cut the RB
1a/b PCR product (419 bp) into two frag-
ments (137 and 282 bp), whereas restriction
cut with Bcl1 resulted in a RB2a/b PCR
product (483 bp) of two (254 and 229) and
those with Mae3 in a RB3/4 PCR product of
3 (265-, 164- and 65-bp) fragments. Gel elec-
trophoresis (2 Ìl restriction product, diluted
with 8 Ìl formamide dye) was handled verti-
cally, using Hydrolink Long Ranger (AT-
Biochem, Malvern, USA)-based electropho-
resis gels at polyacrylamide concentrations
of 0.5% (RB 2a/b, both fragments; RB 3/4,
larger fragments) and 1% (RB1a/b, both
fragments; RB 3/4, small fragment), using an
electrophoresis running time of 14 h at 8 W
for all samples, except for the small RB
3/4-fragment (10 h, 6 W). Autoradiography
of electrophoresis gels was performed using
an X-ray film sensitive to 32P (Eastman-
Kodak, New York, N.Y., USA; fig. 1).
Cycle sequencing of plasmid DNA was
performed after cloning RB templates into a
plasmide vector by using the TA cloning kit
(Invitrogen, Groningen, The Netherlands).
After ligation with the pCR I vector (Invi-
trogen) by a T4 ligase, transformation of
plasmid into Escherichia coli was performed
by using ‘one-shot’ cells. Plasmid DNA was
extracted from overnight cultures by using
the QIAprep-plasmid Mini-kit (Qiagen,
Hilden, Germany) before cycle sequencing
(25 cycles at 96°C/30 s, 50°C/15 s, and
60°C/4 s) with 5 Ìl template (approximately
1 Ìg DNA) was initiated using the PRISM
Ready reaction Dyedesoxy-Terminator Cy-
cle Sequencing Kit (Applied Biosystems,
Weiterstadt, Germany). Unincorporated re-
dundant molecules of the dye were separated
from the extension product by means of
Sephadex column chromatography (Amers-
ham, Braunschweig, Germany). Electropho-
retic separation was performed in a semiau-
tomatic sequencer under denaturating con-
ditions on a 6% polyacrylamide gel contain-
ing urea (model 373 A, Applied Biosystems).
In total, sequencing was performed in four
plasmids of both of the suspicous samples,
respectively, and one control probe, and
each plasmid was sequenced in both orienta-
tions.
Using the SSCP-PCR approach, we
found electrophoretical characteristics dif-
fering from the other samples and negative
controls in 2 of the 29 samples (7%; fig. 2).
These 2 samples were from liver metastases
of 1 cecum and 1 sigma carcinoma. In sam-
ple 11 (patient 27; liver metastasis of a carci-
noma of the sigmoid flexure) two parts and
in sample 12 (patient 32; liver metastasis of a
cecum carcinoma) one part of a band of the
biggest fragment of RB 3/4 were missing. As
cycle sequencing did not reveal RB muta-
tions in these samples, SSCP-PCR of sam-
ples 11 and 12 was repeated, but the pre-
viously demonstrated electrophoretic mobil-
ity shifts could not be reproduced. Thus we
assume that the alterations seen in the first
experiment were artifacts due to tempera-
ture fluctuations between the electrophoresis
gel and the glass top of the electrophoresis
apparatus. This phenomenon is prede-
scribed in the context of the separation of
DNA molecules over a long distance be-
tween the two. Remarkably, both alterations
were found in the 265-bp fragment of RB
3/4, which has a long running distance, in-
deed.
From these results we conclude that RB
mutations are not a common event in ad-
vanced CRC, and thus do not play an impor-
tant role in the development and metastatic
progression of these neoplasms. Further-
more, these findings suggest, that the allelic
changes of RB-1 in CRC described by others
are not associated with mutations of func-
tionally relevant exons.
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